Safety and Efficacy of HER2-Directed ADCs for NSCLC

EP: 1.Introduction and Current Landscape of HER2 in NSCLC

Now Viewing

EP: 2.Safety and Efficacy of HER2-Directed ADCs for NSCLC

EP: 3.Treatment Considerations for Patients With HER2+ NSCLC

EP: 4.Latest Advances and Therapies for HER2+ NSCLC

EP: 5.Unmet Needs and Clinical Considerations for HER2+ NSCLC

EP: 6.Integrating HER2-Directed Therapies Into Standard Care for NSCLC

EP: 7.HER2- Mutation Testing Considerations and Timing

EP: 8.Factors Impacting Use of HER2 Therapies for NSCLC

EP: 9.Incorporating Real-World Evidence for HER2+ NSCLC

EP: 10.Key Takeaways on the Future of HER2 in NSCLC

EP: 11.Real-World Outcomes in HER2-Positive NSCLC

EP: 12.Managing Treatment Challenges in HER2-Directed Therapies

EP: 13.Emerging Horizons in HER2-Directed NSCLC Treatments

EP: 14.Patient Selection and Personalized Treatment Strategies

EP: 15.Navigating Healthcare Access and Decision-Making

Video content above is prompted by the following:

• What factors guide the choice between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine?
• What key insights emerged from pivotal trials like the phase 2 basket DESTINY-Lung01and DESTINY-Lung02?
• How do real-world patient outcomes compare with those seen in clinical trials?
• What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?